Peripheral pterygium, progressive, bilateral
ICD-10 H11.053 is a billable code used to indicate a diagnosis of peripheral pterygium, progressive, bilateral.
Peripheral pterygium, progressive, bilateral, is characterized by a triangular fibrovascular growth that extends from the conjunctiva onto the cornea, affecting both eyes. This condition often arises due to chronic exposure to ultraviolet light, environmental irritants, or genetic predisposition. Clinically, patients may present with symptoms such as redness, irritation, and visual disturbances as the pterygium encroaches on the visual axis. The anatomy involved includes the conjunctiva, sclera, and cornea, with the anterior segment being significantly impacted. Disease progression can lead to increased corneal astigmatism and potential vision loss if the pterygium is not managed appropriately. Diagnostic considerations include a thorough ocular examination, slit-lamp biomicroscopy, and assessment of visual acuity. It is essential to differentiate progressive pterygium from other conjunctival lesions, such as pinguecula or conjunctival cysts, to ensure accurate diagnosis and treatment planning.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
H11.053 specifically covers bilateral progressive peripheral pterygium, which is a growth that affects both eyes and can lead to visual impairment if left untreated. It is essential to distinguish this from unilateral cases and other conjunctival disorders.
H11.053 should be used when both eyes are affected by progressive pterygium. If only one eye is involved, H11.051 should be used. Accurate coding is crucial for treatment planning and insurance reimbursement.
Documentation should include a detailed ocular examination report, noting the presence of bilateral pterygium, symptoms experienced by the patient, visual acuity measurements, and any treatment plans or interventions proposed.
